Vascular endothelial growth factor (VEGF) and its receptors is a central role in pathological and physiological angiogenesis. Bevacizumab (Altuzanʼ 100mg/4ml) is a recombinant human monoclonal antibody which specifically bind to human VEGF and neutralizes biological activity. It has approval from FDA for the treatment colon and rectal cancers. We aimed to investigate the effect of Bevacizumab on neovascularization independent of pedicles caudally based dorsal random-pattern skin flap viability of the flap showing the model in rats.We used weighing 150-250 g female Wistar albino rats in our study. Control and BVZM groups were studied in 2 main groups the Evaluation of flap viability group and the assessment of neovascularization for vascular census group. As an experimental flap model, caudal circulation-based random-pattern skin flap which removed from rats back was chosen. Some of the rats after surgery 2-8 regardless of the viability of the flap pedicles were cut from the days flaps pedicles. The rest of the animals in groups after surgery were sacrificed at 2-5. days and samples were taken for histological analysis. The frequency of flap survival and the mean rate of the survival area were significantly increased in BVZM group than the control group at. 2., 3, 4 and 5th days. Full flap survival rate increased in BVZM group than the control group at 3., 4., and 5th days. The vessel counts of crossections which are stained with immunohistochemical for CD31 were increased in BVZM group than the control group at 2nd day. The increase in vascularization when given chemical agent which is known to antiangiogenic by inhibition of VEGF requires on explanation of possible mechanisms. BVZM's this effect can be explained by such as a pharmacological preconditioning or Anjiopoetin 1/Tie-2, Eph / ephrin or the delta-notch pathways and non-specific growth factors such as alternative ways of angiogenesis due to the blockage of VEGF or VEGF independent mechanism of compensatory angiogenesis can be explained through an. Keywords : Bevacizumab, Neovascularization, VEGF, The Viability of Regardless of Flap Pedicle.
Tez (Uzmanlık)- Süleyman Demirel Üniversitesi, Tıp Fakültesi, Plastik, Rekonstrüktif ve Estetik Cerahi Anabilim Dalı, 2011.
Kaynakça var.
Vascular endothelial growth factor (VEGF) and its receptors is a central role in pathological and physiological angiogenesis. Bevacizumab (Altuzanʼ 100mg/4ml) is a recombinant human monoclonal antibody which specifically bind to human VEGF and neutralizes biological activity. It has approval from FDA for the treatment colon and rectal cancers. We aimed to investigate the effect of Bevacizumab on neovascularization independent of pedicles caudally based dorsal random-pattern skin flap viability of the flap showing the model in rats.We used weighing 150-250 g female Wistar albino rats in our study. Control and BVZM groups were studied in 2 main groups the Evaluation of flap viability group and the assessment of neovascularization for vascular census group. As an experimental flap model, caudal circulation-based random-pattern skin flap which removed from rats back was chosen. Some of the rats after surgery 2-8 regardless of the viability of the flap pedicles were cut from the days flaps pedicles. The rest of the animals in groups after surgery were sacrificed at 2-5. days and samples were taken for histological analysis. The frequency of flap survival and the mean rate of the survival area were significantly increased in BVZM group than the control group at. 2., 3, 4 and 5th days. Full flap survival rate increased in BVZM group than the control group at 3., 4., and 5th days. The vessel counts of crossections which are stained with immunohistochemical for CD31 were increased in BVZM group than the control group at 2nd day. The increase in vascularization when given chemical agent which is known to antiangiogenic by inhibition of VEGF requires on explanation of possible mechanisms. BVZM's this effect can be explained by such as a pharmacological preconditioning or Anjiopoetin 1/Tie-2, Eph / ephrin or the delta-notch pathways and non-specific growth factors such as alternative ways of angiogenesis due to the blockage of VEGF or VEGF independent mechanism of compensatory angiogenesis can be explained through an. Keywords : Bevacizumab, Neovascularization, VEGF, The Viability of Regardless of Flap Pedicle.